Compare Sana Biotechnology Inc (SANA) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Symbotic Inc — how do they compare? Sana Biotechnology Inc trades at $3.77 (market cap $1.13B), while Symbotic Inc trades at $41.2 (market cap $5.41B). The key difference: Symbotic Inc is far larger — about 4.8× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SYM | |
|---|---|---|
Market Cap | $1.13B | $5.41B |
Sector | Health | Technology |
52-Week High | $5.92 | $87.30 |
52-Week Low | $2.68 | $38.57 |
Enterprise Value | $1.05B | $3.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
SYM trades at $41.17, up 2.64% today but facing bearish technical signals with 15 sell indicators. The company reported mixed Q3 2026 results with revenue growth of 21.7% but an earnings miss. Despite negative net income of -$16.94M in 2025, cash flow remains strong at $516.84M and analysts maintain a $60 consensus target with 61% buy ratings.
SYM presents a growth story with expanding revenue and margin improvements, but faces execution risks amid recent earnings misses. The stock offers potential upside to analyst targets but requires careful monitoring of profitability trends and competitive pressures in the warehouse automation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
